History

  • 1993

    Established Ousheng Pharmaceutical in Chengdu, marking the beginning of GoeGoe Honglin's operations in China.

  • 2003

    Relocated manufacturing operations from Chengdu to Beijing and completed Phase I of the Beijing manufacturing facility, establishing Beijing as the company's core manufacturing base.

  • 2006

    Obtained 4 Chinese patents for core technologies: ZL200610153091.8, ZL200610113725.7, ZL200610113984.X, and ZL200610114125.2.

  • 2009

    Recognized as a “National High-Tech Enterprise (China)” and a “Zhongguancun High-Tech Enterprise,” and has maintained both qualifications ever since.

  • 2009

    ALZA Corporation (U.S.A.) presented GoeGoe Honglin with the world's first fully automated mechanical drilling machine for controlled-release tablet testing as a commemorative gift, recognizing its historical significance.

  • 2011

    Officially commenced construction of Phase II at the Beijing Huairou Plant, expanding production capacity.

  • 2019

    Acquired land in Zhenjiang, Jiangsu Province, and initiated plans for a new manufacturing base.

  • 2021

    JUPOPINE®, RoToFier®, and JUPOSHU® successfully passed China's Generic Consistency Evaluation. JUPOPINE® was officially recognized as Nifedipine Controlled-Release Tablets.

  • 2021

    Held the groundbreaking ceremony for the Zhenjiang manufacturing facility and officially commenced construction.

  • 2022

    JUPOPHON® successfully passed China’s Generic Consistency Evaluation.

  • 2024

    Obtained a Chinese utility model patent: ZL202420848264.1.

  • 2024

    Completed construction and inaugurated the Zhenjiang manufacturing facility.

  • 2025

    Zhenjiang Plant officially commenced production, marking the achievement of full-scale production capacity.

  • 2025

    Initiated plans for the Phase II sustained- and controlled-release capsule workshop project.

  • 2026

    Commenced construction of the Phase II sustained- and controlled-release manufacturing facility in Zhenjiang, with a projected annual capacity of 2.7 billion tablets and capsules. Initiated planning for Phase III expansion to support future capacity growth.